More information on this family may be found on the IUPHAR-DB family and introduction pages.
Ghrelin receptors [3] are activated by a 28 amino-acid peptide originally isolated from rat stomach, where it is cleaved from a 117 amino-acid precursor (ENSG00000157017). The human gene encoding the precursor peptide has 83% sequence homology to rat prepro-ghrelin, although the mature peptides from rat and human differ by only two amino acids [12]. Alternative splicing results in the formation of a second peptide, [des-Gln14]ghrelin with equipotent biological activity [9]. A unique post-translational modification (octanoylation of Ser3, catalysed by ghrelin Ο-acyltransferase [MBOAT4, ENSG00000177669], [15]) occurs in both peptides, essential for full activity in binding to the ghrelin receptors in the hypothalamus and pituitary; and the release of growth hormone release from the pituitary [11]. Structure activity studies showed the first five N-terminal amino acids to be the minimum required for binding [2], and receptor mutagenesis has indicated overlap of the ghrelin binding site with those for small molecule agonists and allosteric modulators of ghrelin function [7]. In cell systems, the ghrelin receptor is constitutively active [8], but this is abolished by a naturally occurring mutation (A204E) that results in decreased cell surface receptor expression and is associated with familial short stature [14].
Unless otherwise stated all data refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).
|
Andrews, ZB. (2011) The extra-hypothalamic actions of ghrelin on neuronal function. Trends Neurosci., 34 (1): 31-40. [PMID:21035199]
Angelidis, G; Valotassiou, V; Georgoulias, P. (2010) Current and potential roles of ghrelin in clinical practice. J. Endocrinol. Invest., 33 (11): 823-38. [PMID:21293171]
Briggs, DI; Andrews, ZB. (2011) Metabolic status regulates ghrelin function on energy homeostasis. Neuroendocrinology, 93 (1): 48-57. [PMID:21124019]
Cao, JM; Ong, H; Chen, C. (2006) Effects of ghrelin and synthetic GH secretagogues on the cardiovascular system. Trends Endocrinol. Metab., 17 (1): 13-8. [PMID:16309920]
Cummings, DE. (2006) Ghrelin and the short- and long-term regulation of appetite and body weight. Physiol. Behav., 89 (1): 71-84. [PMID:16859720]
Davenport, AP; Bonner, TI; Foord, SM; Harmar, AJ; Neubig, RR; Pin, JP; Spedding, M; Kojima, M; Kangawa, K. (2005) International Union of Pharmacology. LVI. Ghrelin receptor nomenclature, distribution, and function. Pharmacol. Rev., 57 (4): 541-6. [PMID:16382107]
De Smet, B; Mitselos, A; Depoortere, I. (2009) Motilin and ghrelin as prokinetic drug targets. Pharmacol. Ther., 123 (2): 207-23. [PMID:19427331]
De Vriese, C; Delporte, C. (2007) Influence of ghrelin on food intake and energy homeostasis. Curr Opin Clin Nutr Metab Care, 10 (5): 615-9. [PMID:17693746]
Dezaki, K; Sone, H; Yada, T. (2008) Ghrelin is a physiological regulator of insulin release in pancreatic islets and glucose homeostasis. Pharmacol. Ther., 118 (2): 239-49. [PMID:18433874]
García, EA; Korbonits, M. (2006) Ghrelin and cardiovascular health. Curr Opin Pharmacol, 6 (2): 142-7. [PMID:16483844]
Granata, R; Baragli, A; Settanni, F; Scarlatti, F; Ghigo, E. (2010) Unraveling the role of the ghrelin gene peptides in the endocrine pancreas. J. Mol. Endocrinol., 45 (3): 107-18. [PMID:20595321]
Hosoda, H; Kojima, M; Kangawa, K. (2006) Biological, physiological, and pharmacological aspects of ghrelin. J. Pharmacol. Sci., 100 (5): 398-410. [PMID:16612045]
Kojima, M; Kangawa, K. (2006) Drug insight: The functions of ghrelin and its potential as a multitherapeutic hormone. Nat Clin Pract Endocrinol Metab, 2 (2): 80-8. [PMID:16932262]
Leite-Moreira, AF; Soares, JB. (2007) Physiological, pathological and potential therapeutic roles of ghrelin. Drug Discov. Today, 12 (7-8): 276-88. [PMID:17395087]
Maguire, JJ; Davenport, AP. (2005) Regulation of vascular reactivity by established and emerging GPCRs. Trends Pharmacol. Sci., 26 (9): 448-54. [PMID:16054240]
Nikolopoulos, D; Theocharis, S; Kouraklis, G. (2010) Ghrelin: a potential therapeutic target for cancer. Regul. Pept., 163 (1-3): 7-17. [PMID:20382189]
Olszewski, PK; Schiöth, HB; Levine, AS. (2008) Ghrelin in the CNS: from hunger to a rewarding and memorable meal?. Brain Res Rev, 58 (1): 160-70. [PMID:18308399]
Peeters, TL. (2006) Potential of ghrelin as a therapeutic approach for gastrointestinal motility disorders. Curr Opin Pharmacol, 6 (6): 553-8. [PMID:17011824]
Romero, A; Kirchner, H; Heppner, K; Pfluger, PT; Tschöp, MH; Nogueiras, R. (2010) GOAT: the master switch for the ghrelin system?. Eur. J. Endocrinol., 163 (1): 1-8. [PMID:20421334]
Sanger, GJ. (2008) Motilin, ghrelin and related neuropeptides as targets for the treatment of GI diseases. Drug Discov. Today, 13 (5-6): 234-9. [PMID:18342799]
Seim, I; Josh, P; Cunningham, P; Herington, A; Chopin, L. (2011) Ghrelin axis genes, peptides and receptors: recent findings and future challenges. Mol. Cell. Endocrinol., 340 (1): 3-9. [PMID:21616122]
1. Bedendi, I; Alloatti, G; Marcantoni, A; Malan, D; Catapano, F; Ghé, C; Deghenghi, R; Ghigo, E; Muccioli, G. (2003) Cardiac effects of ghrelin and its endogenous derivatives des-octanoyl ghrelin and des-Gln14-ghrelin. Eur. J. Pharmacol., 476 (1-2): 87-95. [PMID:12969753]
2. Bednarek, M. A., Feighner, S. D., Pong, S. S., McKee, K. K., Hreniuk, D. L., Silva, M. V., Warren, V. A., Howard, A. D., Van der Ploeg, L. H. and Heck, J. V. (2000) Structure-function studies on the new growth hormone-releasing peptide, ghrelin: minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a. J Med Chem., 43: 4370-4376. [PMID:11087562]
3. Davenport, AP; Bonner, TI; Foord, SM; Harmar, AJ; Neubig, RR; Pin, JP; Spedding, M; Kojima, M; Kangawa, K. (2005) International Union of Pharmacology. LVI. Ghrelin receptor nomenclature, distribution, and function. Pharmacol. Rev., 57 (4): 541-6. [PMID:16382107]
4. Esler, WP; Rudolph, J; Claus, TH; Tang, W; Barucci, N; Brown, SE; Bullock, W; Daly, M; Decarr, L; Li, Y; et al.. (2007) Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. Endocrinology, 148 (11): 5175-85. [PMID:17656463]
5. Fraser, GL; Hoveyda, HR; Tannenbaum, GS. (2008) Pharmacological demarcation of the growth hormone, gut motility and feeding effects of ghrelin using a novel ghrelin receptor agonist. Endocrinology, 149 (12): 6280-8. [PMID:18719021]
6. Holst, B., Cygankiewicz, A., Jensen, T. H., Ankersen, M. and Schwartz, T. W. (2003) High constitutive signaling of the ghrelin receptor--identification of a potent inverse agonist. Mol Endocrinol., 17: 2201-2210. [PMID:12907757]
7. Holst, B; Frimurer, TM; Mokrosinski, J; Halkjaer, T; Cullberg, KB; Underwood, CR; Schwartz, TW. (2009) Overlapping binding site for the endogenous agonist, small-molecule agonists, and ago-allosteric modulators on the ghrelin receptor. Mol. Pharmacol., 75 (1): 44-59. [PMID:18923064]
8. Holst, B; Holliday, ND; Bach, A; Elling, CE; Cox, HM; Schwartz, TW. (2004) Common structural basis for constitutive activity of the ghrelin receptor family. J. Biol. Chem., 279 (51): 53806-17. [PMID:15383539]
9. Hosoda, H., Kojima, M., Matsuo, H. and Kangawa, K. (2000) Purification and characterization of rat des-Gln14-Ghrelin, a second endogenous ligand for the growth hormone secretagogue receptor. J Biol Chem., 275: 21995-22000. [PMID:10801861]
10. Katugampola, S. D., Pallikaros, Z. and Davenport, A. P. (2001) [125I-His(9)]-ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue: up-regulation of receptors with athersclerosis. Br J Pharmacol., 134: 143-149. [PMID:11522606]
11. Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H. and Kangawa, K. (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature., 402: 656-660. [PMID:10604470]
12. Matsumoto, M., Hosoda, H., Kitajima, Y., Morozumi, N., Minamitake, Y., Tanaka, S., Matsuo, H., Kojima, M., Hayashi, Y. and Kangawa, K. (2001) Structure-activity relationship of ghrelin: pharmacological study of ghrelin peptides. Biochem Biophys Res Commun., 287: 142-146. [PMID:11549267]
13. Muccioli, G., Papotti, M., Locatelli, V., Ghigo, E. and Deghenghi, R. (2001) Binding of 125I-labeled ghrelin to membranes from human hypothalamus and pituitary gland. J Endocrinol Invest., 24: RC7-RC9. [PMID:11314756]
14. Pantel, J; Legendre, M; Cabrol, S; Hilal, L; Hajaji, Y; Morisset, S; Nivot, S; Vie-Luton, MP; Grouselle, D; de Kerdanet, M; et al.. (2006) Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature. J. Clin. Invest., 116 (3): 760-8. [PMID:16511605]
15. Yang, J; Brown, MS; Liang, G; Grishin, NV; Goldstein, JL. (2008) Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell, 132 (3): 387-96. [PMID:18267071]
|
@GuidetoPHARM Like us on Facebook Privacy and Cookie Policy |


[des-octanoyl]ghrelin has been shown to bind (as [125I]Tyr4-des-octanoyl-ghrelin) and have effects in the cardiovascular system [1], which raises the possible existence of different receptor subtypes in peripheral tissues and the central nervous system. A potent inverse agonist has been identified ([D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P, pD2 8.3; [6]). TZP101, described as a ghrelin receptor agonist (pKi 7.8 and pD2 7.5 at human recombinant ghrelin receptors), has been shown to stimulate ghrelin receptor mediated food intake and gastric emptying but not elicit release of growth hormone, or modify ghrelin stimulated growth hormone release, thus pharmacologically discriminating the orexigenic and gastrointestinal actions of ghrelin from the release of growth hormone [5].